Developing Therapies

New extended-release incretin agonists will be available soon in addition to other DPP inhibitors. Novel concepts in therapy include the dopamine agonist bromocriptine, shown to reduce FFA levels and improve glucose metabolism. The FDA has recently approved a new formulation of bromocriptine for antidiabetic therapy. Another novel class, the sodium glucose-linked transporter protein (SGLT) inhibitors, interfere with renal reabsorption of filtered glucose in the kidney. The prototype SGLT inhibitor is dapagliflozin, and investigational studies show favorably improved glucose control with modest weight loss.

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook


Post a comment